Articles
-
1 week ago |
onclive.com | Caroline Seymour
The addition of atezolizumab (Tecentriq) to bevacizumab (Avastin) and paclitaxel plus cisplatin or carboplatin performed similarly as frontline therapy in patients with persistent or recurrent metastatic cervical cancer with a PD-L1 combined positive score (CPS) of less than 1 or 1 or greater, according to findings from a prespecified exploratory post hoc analysis of the phase 3 BEATcc trial (NCT03556839) that were presented at the 2025 ESMO Gynecologic Cancers Congress.1 At a median...
-
1 week ago |
onclive.com | Caroline Seymour
No statistically significant differences in overall survival (OS) were observed in patients with diffuse large B-cell lymphoma (DLBCL) who received treatment with tisagenlecleucel (tisa-cel; Kymriah), axicabtagene ciloleucel (axi-cel; Yescarta), or lisocabtagene maraleucel (liso-cel; Breyanzi) across FDA-approved indications (log-rank test: χ², 0.773; degrees of freedom [df], 1; P = .379), according to data from a retrospective, observational study presented at the 2025 European Hematology...
-
2 weeks ago |
onclive.com | Caroline Seymour
The FDA has granted fast track designation to CDH17 (CHM-2101 CAR T cells) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1The designation was based on the FDA’s evaluation of CHM CDH17’s ability to improve outcomes for patients with GEP-NETs whose disease progressed on at least 1 prior line of therapy in the advanced or metastatic setting.
-
3 weeks ago |
onclive.com | Caroline Seymour
The European Commission has approved a fixed-duration regimen of acalabrutinib (Calquence) for use in combination with venetoclax (Venclexta), with or without obinutuzumab (Gazyva), for the treatment of patients with treatment-naive chronic lymphocytic leukemia (CLL).1 The approval is based on data from the phase 3 AMPLIFY trial (NCT03836261), which were published in the New England Journal of Medicine and showed a substantial improvement in progression-free survival (PFS) with the...
-
3 weeks ago |
oncnursingnews.com | Caroline Seymour
Luspatercept-aamt (Reblozyl) improved the rate and cumulative duration of red blood cell transfusion independence (RBC-TI) for ≥12 weeks compared with epoetin alfa in patients with transfusion-dependent, erythropoiesis-stimulating agent (ESA)–naive, very low–, low-, or intermediate-risk myelodysplastic syndromes (MDS), according to updated results from the phase 3 COMMANDS trial (NCT03682536) presented at the 2025 American Society of Clinical Oncology Annual Meeting.1 The rate of RBC-TI for...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 119
- Tweets
- 47
- DMs Open
- No
Pretty in pink! Loved connecting with Dr Taplin on the ways in which oncologists are tackling inequitable care in Boston at #NYGU. Looking forward to catching up at the next meeting! @DanaFarber @gotoPER #pcsm #gotoPER @OncLive https://t.co/ADrELoPL2o
RT @OncLive: Behind the scenes with @DrSpratticus and @CarolineM_Sey at #NYGU! Thank you for sitting down with us today. #pcsm @gotoPER htt…
We’re kicking off day 2 of the International Lung Cancer Congress here in Huntington Beach! Keep an eye out for behind the scenes photos and videos with @edgardo_ny @TonyMok9 @KarenReckampMD @NarjustFlorezMD @LudaBazhenovaMD @HatimHusainMD #gotoPER #lcsm #ILCC https://t.co/qgKAZ1fSwO
